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Abstract
Background: ‘‘Non-invasive, faster and less expensive than MRI’’ and ‘‘the eye is a window to the brain’’ are recent slogans
promoting optical coherence tomography (OCT) as a new surrogate marker in multiple sclerosis (MS). Indeed, OCT allows for
the first time a non-invasive visualization of axons of the central nervous system (CNS). Reduction of retina nerve fibre layer
(RNFL) thickness was suggested to correlate with disease activity and duration. However, several issues are unclear: Do a few
million axons, which build up both optic nerves, really resemble billions of CNS neurons? Does global CNS damage really
result in global RNFL reduction? And if so, does global RNFL reduction really exist in all MS patients, and follow a slowly but
steadily ongoing pattern? How can these (hypothesized) subtle global RNFL changes be reliably measured and separated
from the rather gross RNFL changes caused by optic neuritis? Before generally being accepted, this interpretation needs
further critical and objective validation.
Methodology: We prospectively studied 37 MS patients with relapsing remitting (n=27) and secondary progressive (n=10)
course on two occasions with a median interval of 22.460.5 months [range 19–27]. We used the high resolution spectral
domain (SD-)OCT with the Spectralis 3.5 mm circle scan protocol with locked reference images and eye tracking mode.
Patients with an attack of optic neuritis within 12 months prior to the onset of the study were excluded.
Principal Findings: Although the disease was highly active over the observation period in more than half of the included
relapsing remitting MS patients (19 patients/32 relapses) and the initial RNFL pattern showed a broad range, from normal to
markedly reduced thickness, no significant changes between baseline and follow-up examinations could be detected.
Conclusions: These results show that caution is required when using OCT for monitoring disease activity and global axonal
injury in MS.
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Introduction
Multiple sclerosis (MS) is supposed to be a chronic inflammatory
disease of the central nervous system (CNS) causing demyelination
and axonal degeneration [1]. The cause of MS is still unknown.
Underlying pathogenetic mechanisms are regarded to be complex
and heterogeneous.Initiallythey may be triggered from outside of the
CNS, but finally may become compartmentalized within the CNS
[2–9]. In most patients the disease follows a relapsing-remitting
(RRMS), and only rarely a progressive course right from the disease
onset (PPMS, primary progressive MS). After an uncertain period of
time, many RRMS patients change into secondary progression with
or withoutsuperimposed relapses (SPMS,secondary progressiveMS).
Each MS patient follows his own individual disease course [10].
Neither the frequency and severity of relapses nor the disability in the
first years after disease onset nor the lesion load in magnetic
resonance images (MRI) nor any other established parameter nor
biomarkers allow a reliable predication of individual disease courses
so far [11–17]. Merely axonal injury is generally accepted to be the
major pathological correlate of permanent disability in MS [18].
Thus, a method to measure reliably CNS axonal injury, could serve
for disease monitoring in MS [19–20].
With OCT the retina can easily be visualized, its thickness
measured and monitored over time. Initial findings supported
OCT as a non-invasive and useful method. Baseline characteristics
of the retinal nerve fibre layer (RNFL) of MS patients were found
to be heterogeneous and ranged from normal to markedly reduced
thickness [21–22]. The reduction of the RNFL seemed to correlate
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duration, and to the MS subtype - with most significant RNFL
reduction in PPMS and SPMS (with and without ON) [23–24].
However, focal RNFL changes caused by ON are rather gross
[25–27]. They must be clearly separated from any other global
RNFL reduction, which is supposedly subtle, and may even lie
under the detection limit of even advanced SD-OCT techniques
[20,26–27]. Long term studies performed with high resolution SD-
OCT and rather large patient cohorts must provide the RNFL
changes traceable for each included MS patient, to allow the
readers a detailed interpretation [10,28]. RNFL reduction rates
per year, which are calculated by one (baseline) measurement
only, can never replace carefully performed long term follow-up
studies, or serve as ‘scientific proof’ for continuously ongoing
RNFL reduction (‘RNFL thinning’) [10,27]. In contrast, it remains
yet completely unclear whether global RNFL reduction occurs
continuously (‘RNFL thinning’) or stepwise, by accumulation of
focal lesions, or both. Information about ‘RNFL reduction rates
per year’ or ‘RNFL thinning’ should therefore be used with
caution as they might be misleading. But whatever global RNFL
reduction may be caused by, the most important issue is whether
global RNFL reduction exists in all MS patients, or not and if so,
whether subtle global RNFL changes can also be measured in
short observation periods from 6 months to 2 years [23–24]. It is
undisputed that advanced high resolution SD-OCT technique is a
prerequisite [19,20,24,26–29].
For this purpose we studied a large cohort of 27 RRMS and 10
SPMS patients with a new advanced SD-OCT technique over a
long observation period of approximately 22.460.5 years.
Moreover, despite partly intense disease activity with high relapse
rates, none of the included patients had an ON within 12 months
prior to onset of the study. In this study we analysed RNFL
changes in relation to clinical data including age, gender, MS
subtype, disease onset, disease duration, numbers of ON and
relapses (prior to study entry, and during the observation period)
as well as the treatment of each participant.
Methods
Participants
The study was approved by the local Ethics Committee
(Commission of Medical Ethics of Vienna; Ethic Approval/
Registration Number: EK-08-028-0308 and Ethical commission of
the Medical University of Vienna; Ethic Approval/Registration
Number: 414/2008). Informed written consent was obtained from
all patients and volunteers before study entry.
We described the RNFL baseline characteristics of 59 MS (42
RRMS, 17 SPMS) patients in detail previously [22]. All 59 MS
patients were invited to participate in our study. Thirty-seven MS
(27 RRMS, 10 SPMS) patients consented to, whereas 22 patients
had withdrawn from further participation. One of these patients
had an embolic stroke of the left anterior cerebral artery, and one
deteriorated rapidly (EDSS 8.0). The remaining 20 patients
declared that they were not willing for further study participation
(showing no other causes). However, they remained clinically
stable (data not shown).
We studied the 37 MS patients (27 RRMS, 10 SPMS) on two
occasions with a median interval of 22.460.5 months [range 19 to
27 months] prospectively. The patients were consecutively
recruited. MS diagnosis was based on clinical course, MRI and
on cerebrospinal fluid (CSF) analysis [30]. Other differential
diagnoses were consequently ruled out [31–34]. Oligoclonal bands
were found in the CSF samples of all MS-patients. Patients with
other diseases that reduce RNFL thickness such as glaucoma,
anterior ischemic optic neuropathy, high myopia, and congenital
abnormalities of the optic nerves were excluded.
Baseline clinical neurological examinations, visual evoked
potentials (VEP), and ophthalmologic examinations were per-
formed within 7 days. No included patient had an ON within 12
months prior to the onset of the study. A summary of detailed
demographic and clinical data for each included MS patient is
given in table 1.
High Resolution spectral domain OCT
The RNFL measurement was described in detail previously
[22,25–26]. Briefly, we used a high resolution SD-OCT which
combines OCT technology with a confocal scanning laser
ophthalmoscope (Heidelberg Engineering, Heidelberg, Germany,
Spectralis software version 4.0.3.0, Eye Explorer Software 1.6.1.0).
A special eye tracking mode (TrueTrac
TM) and high scanning
speed allows the reduction of artefacts due to eye movement. Each
peripapillary OCT is registered and locked to a reference image.
OCT software can identify previous scan locations and ‘‘guide’’
the OCT laser beam to scan the same location again. To optimize
the signal to noise ratio and image quality 16 frames (B scans) of
the same scanning position were averaged with the Automatic
Real-Time averaging mode (ART mode). All RNFL scans were
acquired in the high-resolution acquisition mode allowing a more
detailed differentiation of retinal layers, with pupil dilation. All
RNFL scans were performed several times by one skilled and
trained observer (N.S.) within one session until at least 3 high-
quality scans were achieved and used for further analysis. The
observer had no knowledge of any clinical data or the specific
baseline data.
Visual function testing, Visual Field Analysis, Visual
evoked potentials (VEP)
Visual function testing, Visual Field Analysis and Visual evoked
potentials were described in detail previously [22,25].
Statistics
The statistics used was described in detail previously [22].
Results
The results of our study performed with the high resolution SD-
OCT can be summarized briefly as follows. Over a median
observation period of 22.460.5 months (range from 19 to 27
months) the RNFL measurements of each MS patient were
unchanged compared to baseline (figure 1). The minimal changes
(62 mm) in some follow up scans were within the intersession
variation (figure 1 and 2) [26,27,29]. Mean globally RNFL values
were found highest in RRMS patients without ON. Mean RNFL
were found lower in RRMS with ON and in SPMS with and
without ON. However, in all 4 groups the individual RNFL values
ranged from normal to markedly reduced, globally or at least in
one of the six peripapillary sectors (figure 1) [22].
The visual and contrast acuity and sensitivity tests (ETDRS,
Sloan and Pelli-Robson-charts), the colour vision test (Lanthony
D-15) and the Humphrey visual field analysis and the visual
evoked potentials showed also no changes compared to the
baseline [22]. Again, neither age nor disease duration nor MS
subtype was found correlated to RNFL changes.
Discussion
In the past few years many OCT studies of MS patients, meta-
analyses and reviews aroused great interest [19,20–24]. OCT was
High Resolution Spectral Domain OCT in MS
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before 1
st OCT examination follow-up
MS age at therapy relapses
* ON age at age at relapses
* therapy
No subtype sex onset right left baseline follow-up
1 RRMS f 34.5 MITOX, GLAT, IFN(b), IFN(a) 7 0 0 40.5 42.25 3 natalizumab
2 RRMS f 18.5 IFN(a), IFN(b) 4 0 0 23.5 25.25 3 natalizumab
3 RRMS f 36.0 MITOX
1, IFN(a) 7 0 0 42.0 43.5 2 natalizumab
4 RRMS f 31.5 none 3 0 0 38.0 40.25 0 none
5 RRMS m 40.0 IFN(a) 3 0 0 45.5 47.5 0 IFN(a)
2;n o n e
6 RRMS f 28.5 IFN(b) 3 0 0 39.0 40.75 2 IFN(b), natalizumab
3
7 RRMS f 43.0 GLAT, IFN(b), none
4 4 0 0 48.0 49.75 3 none, natalizumab
8 RRMS f 40.0 none 2 0 0 42.25 44.0 0 none
9 RRMS m 24.0 none 2 0 0 25.0 26.5 0 none
10 RRMS f 18.0 GLAT, none
5 2 0 0 19.75 21.5 1 none
11 RRMS f 29.75 IFN(a)
6, none 4 0 0 36.0 37.5 1 none
12 RRMS m 31.0 IFN(b) 2 0 0 33.25 35.0 1 IFN(b)
13 RRMS m 51.0 IFN(b) 2 0 0 52.0 54.75 0 IFN(b)
14 RRMS f 23.75 none 2 0 0 27.0 28.5 0 none
7
15 RRMS m 27.5 GLAT 4 0 0 39.0 40.75 0 GLAT
16 RRMS f 30.0 IFN(b)
8, none 4 0 0 46.0 48.5 0 none
17 RRMS m 39.0 IFN(c) 4 0 0 45.0 47.25 1 IFN(c)
18 RRMS f 20.0 IFN(a)
9, none 2 0 0 23.0 25.25 2 none
19 RRMS f 16.0 GLAT 4 0 0 61.0 63.25 0 GLAT
20 RRMS f 20.5 IFN(b)
10, none 5 0 0 28.0 30.25 1 none
21 RRMS f 26.0 IFN(a), IFN(b), MITOX
11, none 9 1 1 32.0 34.0 0 none
22 RRMS f 17.75 IFN(a), IFN(b) 6 1 3 19.75 21.75 1 IFN(b)
12, natalizumab
23 RRMS f 31.0 IFN(a), IFN(b) 4 1 0 36.0 38.25 0 IFN(b)
24 RRMS f 20.0 IFN(b) 8 1 1 47.5 49.0 1 IFN(b)
25 RRMS m 22.5 GLAT, IFN(a), IFN(b), natalizumab 10 0 1 42.5 44.0 0 natalizumab
26 RRMS f 20.0 IFN(a) 3 0 4 41.0 42.5 0 IFN(a)
27 RRMS m 31.0 GLAT
13, none 2 0 1 33.0 35.25 0 none
28 SPMS m 40.0 GLAT, MITOX
14, none 3 0 0 46.5 48.5 0 none
29 SPMS f 13.0 IFN(b), MITOX
15, none 5 0 0 27.0 29.25 2 none
30 SPMS f 38.0 GLAT, none 3 0 0 45.0 47.25 0 none
31 SPMS f 33.5 none 3 0 0 56.0 58.25 0 none
32 SPMS m 28.0 IFN(a), IFN(b) 11 0 0 47.25 49.0 1 IFN(b)
33 SPMS m 25.0 IFN(c), GLAT, IFN(a), IFN(b) 10 1 1 47.5 49.75 1 IFN(b)
34 SPMS m 22.0 IFN(b) 5 1 0 30.5 32.25 2 IFN(b)
16, none
35 SPMS f 16.0 IFN(a), MITOX
17, none 6 0 2 44.25 46.5 2 none
36 SPMS f 50.0 GLAT 4 0 2 53.5 55.75 2 GLAT
37 SPMS m 29.0 IFN(b) 3 0 1 52.0 53.75 0 IFN(b)
ON, optic neuritis;
*, relapses treated with high dose steroid pulse therapy; no included patient had an ON within 12 months prior to the beginning of the study; GLAT, glatiramer-acetate
20 mg subcutaneous once daily; MITOX, mitoxantrone; IFN(a), interferon beta 1a intramuscularly once per week; IFN(b), interferon beta 1a (44 mg) subcutaneous
trice per week; IFN(c), interferon beta 1b (250 mg) subcutaneous alternate day;
1, discontinued (48 mg mitoxantrone per m
2 body surface); none, neither specific immunomodulatory or immunsuppressive therapy, drug holiday;
2, drug withdrawal 9 months after 1
st OCT examination;
3, start 7 months before 2
nd OCT examination;
4, drug withdrawal 12 months before 1
st OCT examination;
5, drug withdrawal 6 months before 1
st OCT examination;
6, drug withdrawal 20 months before 1
st OCT examination;
7, strict vegan diet caused vitamin B12 and folate deficiency;
8, high titres of anti-interferon autoantibodies, drug withdrawal 14 months before 1
st OCT examination;
9, drug withdrawal 25 months before 1
st OCT examination;
10, drug withdrawal 8 months before 1
st OCT examination;
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therapies on MS disease course [19–20]. However, many core
issues are still under intense discussion. Of most importance is that
RNFL measurements performed under essentially the same
conditions but by different OCT devices, differ significantly, and
thus cannot be used or compared interchangeably [29]. The
differences may be explained by the different technologies used
(time domain vs. spectral domain), retinal segmentation algo-
rithms, scanning speed, pupil dilation and other special technical
features such as special eye tracking mode or high resolution
acquisition modes or simply by intersession or inter-observer
variability [29]. In contrast to rather gross ‘focal’ RNFL reduction
rates about 5 mmt o4 0mm, a global RNFL reduction about 2 mm
to 4 mm per year (‘RNFL thinning’) was suggested in MS patients
without ON [20,23]. But ‘RNFL reduction rates per year’ or
‘RNFL thinning’ are statistical definitions only, and at least
completely invalid, when not determined carefully in long-term
follow up studies. Firstly, it is well known that the range of RNFL
thickness in healthy individuals is wide (mean, 97.2 mm69.7;
range from 75 mm to 125 mm) and that RNFL thickness decreases
with age [27]. Even when thousands of values for RNFL thickness
would be averaged to a statistically highly significant and
irrevocably mean, the initial RNFL thickness of the respective
individual MS patient is unknown. Hence, a simple mathematical
correlation between only one (baseline) RNFL value and disease
duration cannot replace follow-up RNFL measurements during
long observation periods. Recently, a minimum observation
period of at least 2 years was suggested to be required to detect
any subtle global RNFL changes in MS patients without ON, if
they exist at all [20].
Secondly, it is yet unknown whether global RNFL reduction
(apart from RNFL changes due to ON) really exists in all MS
patients, and if so, when RNFL reduction may occur and whether
it arises from continuously ongoing or relapsing (remitting) axonal
changes. The hypothesized global RNFL reduction may already
occur years before MS onset, or in very early stages of the disease,
but also in later stages of the disease. Progressive axonal changes
may be elusive in short but obvious in long observations periods.
Accordingly, someone might assume, however that the hypothe-
sized continuous but subtle RNFL reduction should occur when
the disease course changes from the relapsing-remitting to the
secondary progressive phase, or follows a progressive course right
from the beginning in some cases of progressive relapsing-
remitting MS. However, Henderson et al. reported that they did
not detect any significant RNFL reduction (‘RNFL thinning’) in 34
MS patients with progressive disease (18 PPMS, 16 SPMS) in a
Figure 1. Global RNFL changes between baseline and follow-up examination. a, left eye; b, right eye; 1–37, patient 1–37 (see table 1 for
demographic and clinical data); white squares, RRMS without ON (baseline|—|follow-up); black squares, RRMS with ON (baseline|—|follow-up);
white triangles, SPMS without ON (baseline|—|follow-up); black triangles, SPMS with ON (baseline|—|follow-up); black bars, means.
doi:10.1371/journal.pone.0019843.g001
11, mitoxantrone cumulative dose 96 mg per m
2 body surface, drug withdrawal 10 months before 1
st OCT examination;
12, change to natalizumab 2 months after 1
st OCT examination;
13, drug withdrawal 6 months before 1
st OCT examination;
14, mitoxantrone cumulative dose 92 mg per m
2 body surface, drug withdrawal 10 months before 1
st OCT examination;
15, mitoxantrone cumulative dose 92 mg per m
2 body surface, drug withdrawal 26 months before 1
st OCT examination;
16, drug withdrawal 5 months after 1
st OCT examination.
17, mitoxantrone cumulative dose 108 mg per m
2 body surface, drug withdrawal 27 months before 1
st OCT examination;
doi:10.1371/journal.pone.0019843.t001
Table 1. Cont.
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to 895) [24]. From that it is conceivable that (hypothesized) global
RNFL changes either do not exist, or that global RNFL changes
are too subtle to be detected with conventional TD-OCT or that
the observation period was too short. However, most clinical trials
are frequently around 6 to 12 months. Anyway, the supposed
RNFL reduction rates about 2 mm per year are below the
detection limits of time domain- and even most SD-OCT devices
(variations up to 5 mm) [26,29]. Thirdly, rather gross and focal
RNFL changes can hardly be separated from any other
hypothesized subtle, progressive RNFL reduction, and thus may
interfere with any predication of subtle global RNFL changes.
Finally, whatever, the underlying pathogenetic mechanisms
might be, it is completely unclear whether the damage of few
axons along the optic nerves represent really the anatomic and
functional fate of hundred of billions neurons in the entire CNS. In
fact, only rarely the MRI lesion load correlates to the clinical
course of MS patients. Consequently, the question arises why the
RNFL thickness should indeed correlate strictly to MRI
parameters and the clinical course of MS patients. In other
words, why should an hypothesized retrograde trans-synaptic
axonal degeneration have such an effect on the RNFL, but in
contrast does an ON not lead to widespread anterograde axonal
degeneration in the whole CNS? To the best of our knowledge
ON was never found to be correlated to, or proclaimed to cause
diffuse axonal degeneration in the whole CNS, respectively brain
atrophy.
In conclusion, even if most of the MS patients follow a primary
relapsing-remitting course with clinical stable intervals over
months, years or sometimes even decades, that does of course
not rule out subclinical ‘silent’ ongoing degenerative changes [35].
Whether such hypothesized changes really exist in all MS patients
remain to be critically and objectively evaluated. As others we
propose standardized technical requirements [24,27,29,34]. How-
ever, in our long term study performed with advanced SD-OCT
technique we did not find RNFL reduction (‘RNFL thinning’) in a
Figure 2. Variation of RNFL measurements. a, b: variation of RNFL measurements between baseline and follow-up examination in relation to
the total relapses (without ON) before study entry. c, d: variation of RNFL measurements between baseline and follow-up examination in relation to
the relapses (without ON) during the observation period. a, left eye; b, right eye; c, left eye; d, right eye; white squares, RRMS without ON; black
squares, RRMS with ON; white triangles, SPMS without ON; black triangles, SPMS with ON.
doi:10.1371/journal.pone.0019843.g002
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disease activity. Our data suggest that OCT can yet not replace
MRI, or even serve as new surrogate marker in MS.
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